A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years

被引:176
|
作者
Sifuentes, Monica
Doroshow, Robin
Hoft, Richard
Mason, Greg
Walot, Irwin
Diament, Michael
Okazaki, Susan
Huff, Kenneth
Cox, Gerald F.
Swiedler, Stuart J.
Kakkis, Emil D.
机构
[1] BioMarin Pharmaceut Inc, Novato, CA 94949 USA
[2] Harbor UCLA Med Ctr, Dept Pediat, Torrance, CA 90502 USA
[3] Harbor UCLA Med Ctr, Dept Ophthalmol, Torrance, CA 90502 USA
[4] Harbor UCLA Med Ctr, Dept Med, Torrance, CA 90502 USA
[5] Harbor UCLA Med Ctr, Dept Radiol, Torrance, CA 90502 USA
[6] Harbor UCLA Med Ctr, Dept Phys Therapy, Torrance, CA 90502 USA
[7] Genzyme Corp, Clin Res, Cambridge, MA 02142 USA
关键词
cardiac function; efficacy; enzyme replacement therapy; Hurler-Scheie; joint stiffness; laronidase; mucopolysaccharidosis I; Scheie;
D O I
10.1016/j.ymgme.2006.08.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recombinant human alpha-L-iduronidase (Aldurazyme (R), laronidase) was approved as an enzyme replacement therapy for patients with the lysosomal storage disorder, mucopolysaccharidosis I (NIPS I). In order to assess the long-term safety and efficacy of laronidase therapy, 5 of 10 patients in the original laronidase Phase 1/2 clinical trial were re-evaluated after 6 years of treatment. Lysosomal storage was further improved at 6 years (urinary glycosaminoglycans (GAG) excretion decreased 76%; mean liver size at 1.84% of body weight). Shoulder maximum range of motion was maintained or further increased and reached a mean 33.2 (R) and 25.0 (L) degrees gained in flex-ion and 34.0 (R) and 27.3 (L) degrees gained in extension. Sleep apnea was decreased in four of five patients and the airway size index improved. Cardiac disease evaluations showed no progression to heart failure or cor pulmonale but pre-existing significant valve disease did progress in some patients. Substantial growth was observed for the pre-pubertal patients, with a gain of 33 cm (27%) in height and a gain of 31 kg in weight (105%). In general, the evaluated patients reported an improved ability to perform normal activities of daily living. Overall these data represent the first evidence that laronidase can stabilize or reverse many aspects of MPS I disease during long-term therapy and that early treatment prior to the development of substantial cardiac and skeletal disease may lead to better outcomes. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:171 / 180
页数:10
相关论文
共 50 条
  • [31] Novel transporters for MPS I and MPS IIIA enzyme replacement therapy
    Tong, Wenyong
    Sarrazin, Stephane
    Tor, Yitzhak
    Esko, Jeffrey
    MOLECULAR GENETICS AND METABOLISM, 2013, 108 (02) : S92 - S92
  • [32] From diagnosis to follow-up of Fabry patients receiving enzyme replacement therapy in Japan
    Tsukimura, Takahiro
    Togawa, Tadayasu
    Wakamura, Tomotaro
    Kato, Hiroshi
    Sakuraba, Hitoshi
    MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S132 - S132
  • [33] RENAL FOLLOW-UP BIOPSIES IN YOUNG MALE FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY
    Tondel, Camilla
    Bostad, Leif
    Svarstad, Einar
    CLINICAL THERAPEUTICS, 2010, 32 : S105 - S107
  • [34] Cognitive and neuroradiological improvement in three patients with attenuated MPS I treated by laronidase
    Valayannopoulos, V.
    Boddaert, N.
    Barbier, V.
    Le Merrer, M.
    Caillaud, C.
    de Lonlay, P.
    MOLECULAR GENETICS AND METABOLISM, 2010, 100 (01) : 20 - 23
  • [35] A dose optimization study of aldurazyme® (laronidase) in patients with mucopolysaccharidosis I (MPS I).
    Cox, G. F.
    Giugliani, R.
    Martins, A. M.
    Valadares, E. R.
    Clarke, J. T. R.
    Goes, J. E. C.
    Worden, M. A.
    Sidman, M.
    Kakkis, E. D.
    MOLECULAR GENETICS AND METABOLISM, 2007, 90 (03) : 249 - 249
  • [36] Clinical follow-up in a group of Gaucher type I patients switching enzyme replacement therapy from imiglucerase to velaglucerase
    Bembi, Bruno
    Sechi, Annalisa
    Dardis, Andrea
    Deroma, Laura
    Macor, Daniela
    Liva, Giulia
    Ciana, Giovanni
    MOLECULAR GENETICS AND METABOLISM, 2013, 108 (02) : S23 - S24
  • [37] Two cases of late-onset Pompe disease treated with enzyme replacement therapy: Clinical outcome for 3 years follow-up
    Lee, J. H.
    Cho, Y. N.
    Park, H. J.
    Choi, Y. C.
    NEUROMUSCULAR DISORDERS, 2014, 24 (9-10) : 871 - 871
  • [38] Neurocognitive performance in bipolar I patients treated with lithium: A 2 years follow-up longitudinal study
    Diaz-Zuluaga, A. M.
    Valencia-Echeverry, J.
    Vargas, C.
    Lopez-Jaramillo, C.
    BIPOLAR DISORDERS, 2019, 21 : 84 - 84
  • [39] Laronidase treatment in mucopolysaccharidosis I (MPS I) patients less than 5 years old
    Wraith, J. E.
    Beck, M.
    Lane, R.
    Van der Ploeg, A.
    Shapiro, E.
    Guffon, N.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 : 66 - 66
  • [40] Enzyme replacement therapy in mucopolysaccharidosis I patients aged <5 years:: Results of a multinational study of recombinant human α-L-iduronidase (laronidase)
    Guffon, N.
    Beck, M.
    Van der Ploeg, A.
    Lane, R.
    Shapiro, E.
    Wraith, J. E.
    CLINICAL THERAPEUTICS, 2007, 29 : S125 - S125